| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atherosclerosis | 24 | 2023 | 935 | 3.130 |
Why?
|
| Lipoprotein(a) | 7 | 2022 | 113 | 2.000 |
Why?
|
| Cholesterol, LDL | 12 | 2022 | 565 | 1.910 |
Why?
|
| Lipoproteins | 8 | 2022 | 252 | 1.830 |
Why?
|
| Cardiovascular Diseases | 17 | 2023 | 2195 | 1.720 |
Why?
|
| Triglycerides | 7 | 2022 | 603 | 1.690 |
Why?
|
| Coronary Disease | 13 | 2023 | 764 | 1.650 |
Why?
|
| Stroke | 10 | 2023 | 1144 | 1.050 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 8 | 2019 | 98 | 1.010 |
Why?
|
| Brain Ischemia | 4 | 2023 | 292 | 0.940 |
Why?
|
| Cholesterol | 6 | 2018 | 658 | 0.920 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 1054 | 0.910 |
Why?
|
| Troponin T | 13 | 2024 | 261 | 0.900 |
Why?
|
| Biomarkers | 36 | 2024 | 5047 | 0.840 |
Why?
|
| Prediabetic State | 2 | 2018 | 57 | 0.770 |
Why?
|
| Apolipoprotein C-III | 3 | 2022 | 31 | 0.760 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 190 | 0.680 |
Why?
|
| Heart Failure | 11 | 2023 | 2516 | 0.660 |
Why?
|
| Apolipoproteins E | 2 | 2018 | 221 | 0.640 |
Why?
|
| C-Reactive Protein | 10 | 2023 | 527 | 0.610 |
Why?
|
| Risk Factors | 37 | 2023 | 17523 | 0.590 |
Why?
|
| Lipoproteins, LDL | 3 | 2019 | 163 | 0.570 |
Why?
|
| Natriuretic Peptide, Brain | 8 | 2023 | 343 | 0.540 |
Why?
|
| Prospective Studies | 26 | 2024 | 12873 | 0.540 |
Why?
|
| Lipoprotein Lipase | 1 | 2015 | 52 | 0.530 |
Why?
|
| Inflammation | 6 | 2021 | 2522 | 0.530 |
Why?
|
| Carotid Artery Diseases | 3 | 2014 | 196 | 0.520 |
Why?
|
| Hypertension | 2 | 2022 | 1503 | 0.510 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2019 | 849 | 0.500 |
Why?
|
| Lipoproteins, HDL | 2 | 2014 | 144 | 0.470 |
Why?
|
| Metabolic Syndrome | 6 | 2016 | 353 | 0.430 |
Why?
|
| Troponin I | 3 | 2024 | 127 | 0.420 |
Why?
|
| Risk Assessment | 15 | 2021 | 6869 | 0.410 |
Why?
|
| Phospholipases A | 3 | 2005 | 52 | 0.380 |
Why?
|
| Spouse Abuse | 1 | 2010 | 21 | 0.370 |
Why?
|
| Middle Aged | 50 | 2024 | 86204 | 0.360 |
Why?
|
| Peptide Fragments | 7 | 2023 | 1271 | 0.360 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2010 | 216 | 0.360 |
Why?
|
| Population Surveillance | 2 | 2021 | 627 | 0.350 |
Why?
|
| Models, Psychological | 1 | 2010 | 170 | 0.350 |
Why?
|
| Matrix Metalloproteinases | 1 | 2010 | 143 | 0.350 |
Why?
|
| Apolipoproteins | 2 | 2012 | 75 | 0.340 |
Why?
|
| Blood Pressure | 6 | 2024 | 1467 | 0.330 |
Why?
|
| Carotid Arteries | 1 | 2010 | 240 | 0.330 |
Why?
|
| Aged | 35 | 2023 | 70117 | 0.320 |
Why?
|
| Chemokine CCL2 | 4 | 2018 | 203 | 0.320 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 259 | 0.300 |
Why?
|
| Female | 53 | 2024 | 141928 | 0.290 |
Why?
|
| Male | 54 | 2024 | 123000 | 0.280 |
Why?
|
| Humans | 66 | 2024 | 261506 | 0.280 |
Why?
|
| Incidence | 14 | 2021 | 5673 | 0.270 |
Why?
|
| Postprandial Period | 2 | 2016 | 85 | 0.270 |
Why?
|
| Monocytes | 3 | 2019 | 788 | 0.260 |
Why?
|
| Obesity | 6 | 2016 | 2884 | 0.260 |
Why?
|
| Hospitalization | 7 | 2019 | 2083 | 0.250 |
Why?
|
| Coronary Artery Disease | 4 | 2014 | 1011 | 0.250 |
Why?
|
| Albuminuria | 2 | 2022 | 113 | 0.250 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 136 | 0.240 |
Why?
|
| Cholesterol, HDL | 5 | 2014 | 341 | 0.240 |
Why?
|
| United States | 18 | 2021 | 15433 | 0.230 |
Why?
|
| Proportional Hazards Models | 8 | 2017 | 4988 | 0.220 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 77 | 0.220 |
Why?
|
| Lipids | 5 | 2014 | 644 | 0.220 |
Why?
|
| Angiopoietin-like Proteins | 1 | 2022 | 14 | 0.210 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 719 | 0.210 |
Why?
|
| Myocardial Infarction | 3 | 2024 | 1374 | 0.210 |
Why?
|
| Models, Biological | 1 | 2010 | 3254 | 0.200 |
Why?
|
| Peripheral Arterial Disease | 2 | 2016 | 267 | 0.190 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2020 | 19 | 0.190 |
Why?
|
| Apolipoproteins B | 2 | 2019 | 106 | 0.190 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 4892 | 0.190 |
Why?
|
| Renin-Angiotensin System | 1 | 2021 | 103 | 0.180 |
Why?
|
| Galectin 3 | 1 | 2021 | 138 | 0.180 |
Why?
|
| Diet, Western | 1 | 2019 | 23 | 0.180 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 34 | 0.180 |
Why?
|
| Blood Glucose | 4 | 2018 | 1244 | 0.180 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2010 | 66 | 0.170 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2024 | 421 | 0.160 |
Why?
|
| Linear Models | 4 | 2017 | 1085 | 0.160 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2018 | 38 | 0.160 |
Why?
|
| Interleukin-18 | 2 | 2023 | 100 | 0.160 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2017 | 10 | 0.160 |
Why?
|
| Adipokines | 1 | 2018 | 96 | 0.150 |
Why?
|
| Protein Precursors | 2 | 2021 | 240 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2021 | 603 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2014 | 100 | 0.140 |
Why?
|
| Fatty Acids | 1 | 2019 | 448 | 0.140 |
Why?
|
| Alzheimer Disease | 1 | 2024 | 855 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 182 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 483 | 0.140 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 41 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2021 | 846 | 0.130 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.130 |
Why?
|
| Risk | 5 | 2018 | 1972 | 0.130 |
Why?
|
| White Matter | 1 | 2017 | 195 | 0.130 |
Why?
|
| Life Style | 1 | 2018 | 612 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 1362 | 0.130 |
Why?
|
| Prognosis | 9 | 2023 | 21713 | 0.130 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2014 | 44 | 0.120 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2014 | 51 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2017 | 264 | 0.120 |
Why?
|
| Subtilisins | 1 | 2014 | 14 | 0.120 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 333 | 0.120 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 153 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 4549 | 0.120 |
Why?
|
| Athletes | 1 | 2014 | 73 | 0.120 |
Why?
|
| Particle Size | 1 | 2014 | 182 | 0.120 |
Why?
|
| Cohort Studies | 10 | 2018 | 9244 | 0.120 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 227 | 0.120 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 423 | 0.120 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 610 | 0.120 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 29902 | 0.120 |
Why?
|
| Brain Infarction | 1 | 2013 | 31 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 4314 | 0.110 |
Why?
|
| Cognition | 1 | 2019 | 968 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 657 | 0.110 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 63 | 0.110 |
Why?
|
| Exome | 1 | 2018 | 1239 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2018 | 6100 | 0.110 |
Why?
|
| Prevalence | 3 | 2017 | 3260 | 0.110 |
Why?
|
| Lactic Acid | 1 | 2014 | 305 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2015 | 235 | 0.110 |
Why?
|
| Phospholipases A2 | 3 | 2006 | 43 | 0.110 |
Why?
|
| Follow-Up Studies | 9 | 2021 | 14889 | 0.100 |
Why?
|
| Brain | 3 | 2024 | 4113 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 259 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 551 | 0.100 |
Why?
|
| Weight Loss | 3 | 2011 | 627 | 0.100 |
Why?
|
| Nursing Evaluation Research | 1 | 2010 | 13 | 0.100 |
Why?
|
| Calcinosis | 2 | 2014 | 423 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2010 | 71 | 0.090 |
Why?
|
| Dehydroepiandrosterone | 1 | 2010 | 38 | 0.090 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 77 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2010 | 91 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 1489 | 0.090 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 67 | 0.090 |
Why?
|
| Prolactin | 1 | 2010 | 155 | 0.090 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2010 | 121 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 221 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2016 | 1048 | 0.090 |
Why?
|
| Sex Factors | 4 | 2017 | 2139 | 0.090 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2011 | 160 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2014 | 2203 | 0.090 |
Why?
|
| Logistic Models | 2 | 2014 | 3441 | 0.090 |
Why?
|
| Immunoassay | 3 | 2005 | 216 | 0.090 |
Why?
|
| Myocardial Revascularization | 1 | 2009 | 134 | 0.090 |
Why?
|
| Dementia | 1 | 2014 | 453 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2014 | 4320 | 0.080 |
Why?
|
| Carotid Stenosis | 1 | 2010 | 176 | 0.080 |
Why?
|
| Alleles | 1 | 2015 | 2437 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2010 | 388 | 0.080 |
Why?
|
| Women's Health | 1 | 2010 | 205 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2011 | 769 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 786 | 0.080 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2008 | 58 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 980 | 0.080 |
Why?
|
| Postmenopause | 2 | 2020 | 378 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 4971 | 0.080 |
Why?
|
| Interleukin-6 | 3 | 2023 | 1038 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2019 | 2450 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 793 | 0.070 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 159 | 0.070 |
Why?
|
| Health Promotion | 1 | 2010 | 502 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2307 | 0.070 |
Why?
|
| Phenotype | 2 | 2014 | 6295 | 0.070 |
Why?
|
| Age Factors | 4 | 2018 | 5377 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2265 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2014 | 2086 | 0.070 |
Why?
|
| Cystatin C | 2 | 2016 | 54 | 0.070 |
Why?
|
| Comorbidity | 3 | 2017 | 2352 | 0.070 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 787 | 0.060 |
Why?
|
| Adult | 8 | 2022 | 77950 | 0.060 |
Why?
|
| Odds Ratio | 4 | 2014 | 2316 | 0.060 |
Why?
|
| Leptin | 3 | 2018 | 295 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2005 | 310 | 0.060 |
Why?
|
| Caveolins | 1 | 2003 | 73 | 0.060 |
Why?
|
| Azetidines | 2 | 2013 | 87 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 185 | 0.060 |
Why?
|
| Cytokines | 2 | 2010 | 2809 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10331 | 0.060 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2010 | 604 | 0.060 |
Why?
|
| Ezetimibe | 2 | 2013 | 101 | 0.060 |
Why?
|
| Simvastatin | 2 | 2013 | 106 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 7702 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 246 | 0.050 |
Why?
|
| tau Proteins | 1 | 2024 | 216 | 0.050 |
Why?
|
| Adiponectin | 2 | 2018 | 163 | 0.050 |
Why?
|
| Pulse Wave Analysis | 1 | 2021 | 45 | 0.050 |
Why?
|
| Liver | 1 | 2011 | 2961 | 0.050 |
Why?
|
| Energy Intake | 1 | 2004 | 515 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 650 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5061 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 5539 | 0.050 |
Why?
|
| Apolipoprotein E4 | 1 | 2019 | 48 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2014 | 1945 | 0.040 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 9 | 0.040 |
Why?
|
| Insulin | 3 | 2014 | 1454 | 0.040 |
Why?
|
| Sirolimus | 1 | 2002 | 814 | 0.040 |
Why?
|
| Memory, Episodic | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cerebral Infarction | 1 | 2017 | 59 | 0.040 |
Why?
|
| Factor VIII | 1 | 2017 | 75 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 218 | 0.040 |
Why?
|
| Echocardiography | 1 | 2023 | 1182 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2017 | 205 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 755 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2017 | 684 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 79 | 0.030 |
Why?
|
| Smoking | 2 | 2016 | 2440 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 1375 | 0.030 |
Why?
|
| Cause of Death | 1 | 2019 | 752 | 0.030 |
Why?
|
| Proteins | 1 | 2004 | 1963 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 303 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 335 | 0.030 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2017 | 348 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1178 | 0.030 |
Why?
|
| Retirement | 1 | 2014 | 22 | 0.030 |
Why?
|
| Lipocalins | 1 | 2014 | 54 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 255 | 0.030 |
Why?
|
| Football | 1 | 2014 | 37 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 1323 | 0.030 |
Why?
|
| Sitosterols | 1 | 2013 | 10 | 0.030 |
Why?
|
| Absorption | 1 | 2013 | 81 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 2594 | 0.030 |
Why?
|
| Rosuvastatin Calcium | 1 | 2013 | 43 | 0.030 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2014 | 81 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 2014 | 184 | 0.030 |
Why?
|
| Fluorobenzenes | 1 | 2013 | 39 | 0.030 |
Why?
|
| Niacin | 1 | 2013 | 61 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 166 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 269 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 118 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 1582 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2014 | 131 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1225 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 590 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2014 | 189 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 150 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2014 | 276 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 177 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2013 | 210 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 349 | 0.030 |
Why?
|
| Reference Values | 1 | 2014 | 1099 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2011 | 84 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2014 | 598 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2011 | 56 | 0.030 |
Why?
|
| CD11c Antigen | 1 | 2011 | 55 | 0.020 |
Why?
|
| Caloric Restriction | 1 | 2011 | 88 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2011 | 172 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2014 | 1163 | 0.020 |
Why?
|
| Necrosis | 1 | 2011 | 580 | 0.020 |
Why?
|
| Diet, High-Fat | 1 | 2011 | 241 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 4298 | 0.020 |
Why?
|
| Fatty Liver | 1 | 2011 | 235 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3033 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 1084 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 1538 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 891 | 0.020 |
Why?
|
| Calcium | 1 | 2014 | 1537 | 0.020 |
Why?
|
| Myocardium | 1 | 2014 | 1313 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 2588 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 3472 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 5637 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2006 | 31 | 0.020 |
Why?
|
| Static Electricity | 1 | 2006 | 58 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 731 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 5767 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 756 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2006 | 568 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2014 | 1589 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 1509 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2005 | 37905 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4109 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 1183 | 0.020 |
Why?
|
| Microspheres | 1 | 2005 | 210 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 34495 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 717 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 1472 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2004 | 87 | 0.010 |
Why?
|
| Animals | 3 | 2019 | 59536 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12221 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2005 | 519 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 459 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 337 | 0.010 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 210 | 0.010 |
Why?
|
| Caveolin 1 | 1 | 2003 | 204 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 957 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2013 | 3518 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 6942 | 0.010 |
Why?
|
| Antibodies | 1 | 2003 | 838 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 3438 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2927 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2003 | 3536 | 0.010 |
Why?
|
| Texas | 1 | 2008 | 6311 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 5114 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 4938 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 21445 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31252 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2013 | 32848 | 0.010 |
Why?
|